News

Close to 20 percent of breast cancers are triple-negative, a type of tumor that lacks the three most common receptors that fuel most breast cancer growth. These tumors

The EMA will now initiate its review of the XELJANZ MAA. This application provides additional information to the original MAA submission, including data from the Phase 3 ORAL

The Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with

Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated as adjunct to diet and maximally tolerated statin therapy to treat adults with heterozygous familial hypercholesterolemia (HeFH)

Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million),

IPF results from the build-up of scar tissue (fibrosis) in the lungs, which prevents normal uptake of oxygen. Scar tissue is comprised of collagen fibres which, when excessively

Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain

Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. "Over the last

Taltz, which is administered as an injection, is indicated for patients who are candidates for systemic therapy or phototherapy. It is a humanized IgG4 monoclonal antibody that selectively